Cancer Communications
indexed by SCI
BMC
Home > About the cover



Volume:36 Issue:7   2017

Metformin (1,1-dimethylbiguanide hydrochloride), an inexpensive and well-tolerated oral agent commonly used in the first-line treatment of type 2 diabetes, has become the focus of intense research as a candidate anticancer agent. Metformin can be used as a sensitizer or be combined with conventional chemotherapeutic agents and radiotherapy to combat cancer. Metformin plays an important role in targeting cancer stem cells (CSCs) and reversing the epithelial-mesenchymal transition (EMT), a critical process in cancer metastasis. The cover art shows the possible signaling pathways involved in the anticancer effects of metformin. For more details, please read the paper on pages 289-297 of the present CJC issue. (The original cover art is provided by Yi Lu and colleagues.)




© Chinese Journal of Cancer

Sun Yat-sen University Cancer Center

651 Dongfeng Road East, Guangzhou 510060, P. R. China